Home > Oncology > Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy

Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy

Principal Investigator
Dr Daniel Olson, The University of Chicago Comprehensive Cancer Center, IL, USA
Conference
ASCO 2020
Trial
Phase 2
Results of a phase 2 study showed that treatment with pembrolizumab plus low-dose ipilimumab has a significant antitumor activity and is tolerable in melanoma patients who progress on first-line anti-PD1/PDL1 therapy. For patients with unresectable or metastatic melanoma, first-line treatment with an anti-PD1 or anti-PDL1 antibody is now standard-of-care. The optimal second-line treatment after progression on the anti-PD1/PDL1 treatment is not known yet. Long-term follow-up data of the KEYNOTE-6 study has shown that for those patients who progressed on the PD1 antibody pembrolizumab and received ipilimumab (3 mg/kg), an anti-CTLA4 antibody, in second line, the long-term response rate was 15% with a median overall survival (OS) of 13.6 months [1]. However, ipilimumab given in a dose of 3 mg/kg comes with high toxicity. Data from both KEYNOTE-029 and Checkmate 511 demonstrated that low-dose ipilimumab (1 mg/kg) in combination with an anti-PD1 antibody shows...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on